chemotherapy and allohsct in the treatment of all
Published 2 years ago • 42 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:56
the feasibility of chemotherapy-free regimens without allogeneic transplantation in mrd- ph all
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:24
conventional approaches for all targeted therapies in allo-hsct
-
2:34
the burden of vte in cancer patients: impacts and novel treatments
-
4:09
veno-occlusive disease as a post-transplant complication of hsct
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:39
optimizing chemotherapy in aml
-
2:36
intensive induction chemotherapy vs hma/ven in npm1-mutant aml: a retrospective study
-
3:03
allosct outcomes after immunotherapy vs chemotherapy in patients with r/r nhl: a retrospective study
-
1:38
which patients with all should be taken to transplant?
-
8:57
outcomes of sct in t-all and t-lbl
-
2:41
cell avidity as a predictor of t-cell efficacy
-
5:14
are transplantation and chemotherapy still necessary for all patients with ph all?
-
2:08
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
1:25
how the role of transplant in all is evolving with the introduction of novel immunotherapies
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸